Gilead sales and marketing update

The U.K.’s NICE issued draft guidance recommending the use of Epclusa sofosbuvir/velpatasvir from Gilead to treat all genotypes of chronic HCV infection. The recommendation is contingent on Gilead providing the drug at an undisclosed discount.

NICE said Epclusa was cost-effective for all subgroups in all HCV genotypes at a threshold of L20,000 ($26,116) per quality-adjusted life year (QALY) gained, excluding patients with untreated HCV genotype 2 infection who do not have cirrhosis and who can receive interferon. Epclusa costs L38,980 ($50,900) for a 12-week course prior to the discount, according to the agency. The recommended dose of Epclusa is 1 tablet given once daily for 12 weeks. ...